MaxCyte Reports Q3 2026 Revenue Growth and Raised Full-Year Guidance Following Akron Bio Acquisition
MaxCyte (MXCT) reported strong third-quarter results for 2026, with total revenue reaching $10.2 million, a 49% increase year-over-year. This growth was primarily driven by increased milestone revenues and robust instrument sales, including a doubling of instrument revenue to $2.8 million. The company's strategic platform license revenue also saw significant contributions from commercial royalties related to CASGEVY. The integration of Akron Bio has fundamentally transformed MaxCyte's scale, with pro forma 2026 revenue expected to exceed $60 million. Management raised full-year 2026 revenue guidance to at least $34.5 million due to stronger royalty performance. Additionally, the acquisition has significantly improved the company's financial profile by reducing projected cash burn and diversifying its customer base, with the largest customer concentration dropping from 27% to 14%.
Tickers: $MXCT
Topics: acquisition financial guidance milestone revenue revenue growth